FWB:MRK

Track all markets on TradingView - Graphs are not on time
Merck announced the launch of the first bio-based solvent portfolio for high-performance liquid chromatography (HPLC), aimed at reducing environmental impact while maintaining analytical performance. The new solvents are produced from renewable feedstocks and deliver on average 25.9% lower carbon emissions compared to conventional fossil-based alternatives.

Designed as drop-in replacements for commonly used solvents such as acetonitrile, methanol, and ethanol, the products allow laboratories to transition without modifying existing analytical methods. The company said this ensures seamless adoption in applications including drug development, quality control, environmental testing, and diagnostics.

Merck emphasized that the innovation supports its broader sustainability strategy by helping customers reduce greenhouse gas emissions without compromising precision or reliability in laboratory workflows.
💬 🔗
Author
The Investor 04-21-26
Daiichi Sankyo and Merck & Co. announced that the U.S. Food and Drug Administration has granted Priority Review to the Biologics License Application for ifinatamab deruxtecan (I-DXd), a potential new treatment for extensive-stage small cell lung cancer (ES-SCLC).

The therapy is intended for adult patients whose disease has progressed after platinum-based chemotherapy, an area with limited treatment options. If approved, it would become a first-in-class B7-H3 directed antibody-drug conjugate.

The application is supported by results from the Phase 2 IDeate-Lung01 trial, with additional data from the Phase 1/2 IDeate-PanTumor01 study. The drug had previously received Breakthrough Therapy Designation from the FDA in August 2025.

The FDA is reviewing the application under Priority Review, as well as its Real-Time Oncology Review and Project Orbis programs, which aim to accelerate access to promising cancer treatments. A regulatory decision is expected by October 10, 2026.

Overall, the development marks a significant step toward a new treatment option for a highly aggressive cancer type, with potential to address unmet medical needs in late-stage small cell lung cancer.
💬 🔗
Author
WS Investor 04-14-26
Merck KGaA has completed the acquisition of the chromatography business of JSR Life Sciences, strengthening its capabilities in biopharmaceutical manufacturing.

The deal adds advanced Protein A chromatography technologies, including Amsphere™ resins, to Merck’s downstream processing portfolio, enabling more efficient and scalable purification of monoclonal antibodies. This is expected to enhance productivity and support reliable manufacturing from development through commercial scale.

The acquisition also brings a Belgium-based team of more than 50 employees with expertise in chromatography solutions, further reinforcing Merck’s technical capabilities and customer support offering.

Merck stated that the expanded portfolio will help biopharma companies accelerate production processes and improve access to critical therapies, aligning with growing demand for scalable biologics manufacturing solutions.
💬 🔗
Author
The Investor 04-02-26
Merck & Co., Inc. reported fourth-quarter and full-year 2025 results showing resilient performance driven by oncology and animal health, while highlighting significant progress across its late-stage pipeline.

Fourth-quarter worldwide sales rose 5% to $16.4 billion, with GAAP EPS of $1.19 and non-GAAP EPS of $2.04. For full-year 2025, Merck generated $65.0 billion in worldwide sales, up 1% year over year, supported by 7% growth in KEYTRUDA/KEYTRUDA QLEX sales to $31.7 billion, $1.4 billion in WINREVAIR sales, and strong Animal Health growth of 8%. These gains were partly offset by a sharp decline in GARDASIL/GARDASIL 9 sales.

During 2025, Merck reported positive results from 18 Phase 3 trials, expanded its pipeline through acquisitions and licensing deals, and received FDA National Priority Vouchers for key late-stage assets. Looking ahead, the company expects 2026 worldwide sales of $65.5–$67.0 billion and non-GAAP EPS of $5.00–$5.15, reflecting a one-time charge related to the Cidara Therapeutics acquisition.

Source: Merck & Co., Inc. press release
💬 🔗
Author
WS Investor 02-03-26
Merck announced that China’s National Medical Products Administration (NMPA) has approved pimicotinib as a systemic treatment for adults with symptomatic tenosynovial giant cell tumor (TGCT) where surgery may cause functional limitation or severe morbidity. This marks the first regulatory approval globally for pimicotinib, a CSF-1R inhibitor developed by Abbisko Therapeutics and commercialized worldwide by Merck, strengthening the company’s position in rare tumor treatments.

The approval is based on results from the global Phase 3 MANEUVER study, in which pimicotinib demonstrated a statistically significant improvement in objective response rate at week 25 versus placebo (54.0% vs. 3.2%), alongside meaningful improvements in mobility, physical function, pain, and stiffness. Longer-term follow-up showed that more than 75% of patients achieved a response per RECIST v1.1, with the treatment remaining generally well tolerated.

Merck stated that additional regulatory submissions for pimicotinib are ongoing globally, following designations such as FDA Breakthrough Therapy and EMA PRIME. The company plans to make the therapy available to patients in China as quickly as possible while continuing international expansion efforts.
💬 🔗
Author
WS Investor 12-23-25
High-Performance Supercomputer Launched to Advance AI Innovation and Scientific Discovery

Equinix (Nasdaq: EQIX), Lenovo and Merck KGaA, Darmstadt, Germany have launched a new high-performance computer hosted in an Equinix AI-ready data center in Germany. Built on Lenovo ThinkSystem servers with liquid cooling, the system will accelerate Merck’s work across life science, healthcare and electronics — from drug discovery to materials for next-generation semiconductor chips.

The hybrid cloud HPC platform improves Merck’s ability to use AI and advanced analytics, offering scalable compute power while supporting sustainability goals. Equinix provides the global, interconnected infrastructure needed for large-scale AI workloads, and Lenovo’s liquid-cooling technology boosts efficiency for demanding scientific tasks.

The partnership aims to advance scientific discovery by combining digital infrastructure, high-performance compute and AI to drive faster, more sustainable innovation.
💬 🔗
Author
WS Investor 11-20-25